Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. [More]
Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel. [More]
Researchers make significant progress in improving survival of adult patients with low-grade gliomas

Researchers make significant progress in improving survival of adult patients with low-grade gliomas

Using clinical data collected over the past decade through a U.S. cancer registry, researchers at the University of California, San Diego School of Medicine demonstrated that significant strides have been made in improving the survival of adult patients with low-grade gliomas, a slow-growing yet deadly form of primary brain cancer. [More]
NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

A researcher at North Dakota State University, Fargo, is receiving a four-year $1.35 million research project grant from the National Cancer Institute of the National Institutes of Health to develop a targeted treatment for colorectal cancer. [More]
SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, antiemetics expert and ESMO spokesperson Fausto Roila said, putting into perspective the results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. [More]
Low BMI linked to poorer survival in advanced colorectal cancer

Low BMI linked to poorer survival in advanced colorectal cancer

Although being overweight with a high body-mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine. [More]
Two-thirds of patients with T4a larynx cancer not receiving total laryngectomy

Two-thirds of patients with T4a larynx cancer not receiving total laryngectomy

Despite findings of previous studies and published guidelines, nearly two-thirds of patients with T4a larynx ("voice box") cancer are not receiving a total laryngectomy (surgical removal of the larynx), the recommended form of treatment, and as a result, have significantly worse survival rates versus those treated with a total laryngectomy, a new study published in the International Journal of Radiation Oncology, Biology and Physics by experts at Penn Medicine found. [More]
Nanoparticles packed with chemotherapy drug and coated with chitosan target cancer stem-like cells

Nanoparticles packed with chemotherapy drug and coated with chitosan target cancer stem-like cells

Nanoparticles packed with a clinically used chemotherapy drug and coated with an oligosaccharide derived from the carapace of crustaceans might effectively target and kill cancer stem-like cells, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
Damon Runyon creates new award to increase number of physician-scientists

Damon Runyon creates new award to increase number of physician-scientists

Physician-scientists are crucial to moving scientific discoveries from the lab to patients, but their numbers have been dwindling just when they are needed most, particularly in cancer research, as the number of cancer cases is projected to increase by 45 percent in the next fifteen years and elevate cancer to the leading cause of death in America. [More]
NIBIB-supported researchers create platelet-like particles to control excessive bleeding, augment clotting

NIBIB-supported researchers create platelet-like particles to control excessive bleeding, augment clotting

NIBIB-supported researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control excessive bleeding following traumatic injury or in individuals with impaired clotting due to an inherited condition or as a result of certain medications or chemotherapy. [More]
Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

America's oldest cancer center and one of the world's newest oncology centers are partnering to improve access to cancer prevention, screening and care for the people of Nigeria. Roswell Park Cancer Institute and Lakeshore Cancer Center have announced an affiliation that will see Roswell Park faculty providing clinical consultations to assist LCC oncologists, who will also have access to both training at RPCI and continuing professional education seminars they can participate in remotely. [More]
Aeterna Zentaris recruits patients for ZoptEC Phase 3 study in women with advanced endometrial cancer

Aeterna Zentaris recruits patients for ZoptEC Phase 3 study in women with advanced endometrial cancer

Aeterna Zentaris Inc. today announced it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. [More]
Study may lead to better treatments for children with neuroblastoma

Study may lead to better treatments for children with neuroblastoma

Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children. [More]
PharmaMar begins PM1183 phase III study in patients with platinum-resistant ovarian cancer

PharmaMar begins PM1183 phase III study in patients with platinum-resistant ovarian cancer

PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication. [More]
Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020. [More]
Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. [More]
CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma. [More]
SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

In research published in Cancer Cell, Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University, has, for the first time, found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit. [More]
No overall survival benefit for bevacizumab in ovarian cancer

No overall survival benefit for bevacizumab in ovarian cancer

Addition of bevacizumab to first-line platinum-based chemotherapy does not improve overall survival in women with ovarian cancer, according to the mature data of the ICON7 trial. [More]
Growth of lymph node metastases takes advantage of existing blood vessels

Growth of lymph node metastases takes advantage of existing blood vessels

While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital Cancer Center may have found at least one reason why. [More]
Advertisement
Advertisement